{"name":"Seikagaku Corporation","slug":"seikagaku-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CONDOLIASE","genericName":"CONDOLIASE","slug":"condoliase","indication":"Disorder of lumbar disc","status":"marketed"},{"name":"SI-722","genericName":"SI-722","slug":"si-722","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Joycle","genericName":"diclofenac etalhyaluronate sodium","slug":"diclofenac-etalhyaluronate-sodium","indication":"Osteoarthritis of hip","status":"marketed"}]}],"pipeline":[{"name":"CONDOLIASE","genericName":"CONDOLIASE","slug":"condoliase","phase":"marketed","mechanism":"Enzyme","indications":["Disorder of lumbar disc"],"catalyst":""},{"name":"Joycle","genericName":"diclofenac etalhyaluronate sodium","slug":"diclofenac-etalhyaluronate-sodium","phase":"marketed","mechanism":"Prostaglandin E2 receptor EP2 subtype","indications":["Osteoarthritis of hip","Osteoarthritis of knee"],"catalyst":""},{"name":"SI-722","genericName":"SI-722","slug":"si-722","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxNUzN1MEE0NTlVbzNzYkRsc2ZNVXFjX002SEpKcW91U3gzNGRrRVdyakd2bjBVbWlUSjVrTkZPekxuOERHeWt4dEwxNVR4YzZkamZiY21td2N3b2RNdWNNeVNNcjV3ZmliWlJ1ZmNwMTBudmktaUI0RkJzekpxa3QwY2t0all1Si1LZ2FNN21ZcTZuNFBwZWhfSld0cjA4MEVMdktmQ1FTM3ZrM2V5cFVMbDdwVTFQY01yWjZkX04yNnlRVTVxbXlKLTd3MHNXc2habEp0TTNYcXpuaG42SkJMcmVtaHNxUmt3RVdQbTZDNGQwUjR6LWVWN0NvbEpvenlkWk5ZWXp3?oc=5","date":"2026-03-12","type":"trial","source":"StreetInsider","summary":"Dry Eye Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight - StreetInsider","headline":"Dry Eye Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPSjRNQm50RTJSdkRYSGxIaHljTVkxWUN0bGR4Nkhvb1N0LWw5RTJKRThtMTh1N1hJQTB5dl90eFI3aWpKNTdlaGJZd1lhRFY1dXFnYnY5VHluRmU1a3pfcHR3dlRBRTk1RkNGUEVSVG94bkV3c19oNUxCcmtQNGlqWlM5ank0VkVleG0xc2Z3ODdXdVIw?oc=5","date":"2026-01-06","type":"regulatory","source":"BioSpace","summary":"FDA Went Against Adcomm Votes More, Held Fewer Meetings in 2025 - BioSpace","headline":"FDA Went Against Adcomm Votes More, Held Fewer Meetings in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxNa1ZCNlJqWm1HMGJma192eUFmYURyWWhPLWwtS19GQS0wSjAwdUlEdXJPclBaMlZNVjgtZkJIdERPNWZSd28zY29BVmtHRHpBSDdvOWt0R0JXZXV3VnZ5cEZjY1A2N1pNU1dLS29ic2ZuV2ItRldhdzhOa3hma0gyczljUlhHd1AwUlhoRG9VMnlSV0kyVW4tZGdMWlNvc2NpWHFGLVFiVUwyZUlKaUxvYWoyMDlnaUpYU0NBemxGNnlrcGtjM2wyeGpTbUMybVE5VEw0VW1kOFVHWkZCUWZINzE3OXlnQ0FzNlRZNFFTeHZIRjZr?oc=5","date":"2025-08-04","type":"trial","source":"PR Newswire","summary":"Interstitial Cystitis Market to Grow Rapidly at a CAGR of 4% During the Study Period (2020-2034) | DelveInsight - PR Newswire","headline":"Interstitial Cystitis Market to Grow Rapidly at a CAGR of 4% During the Study Period (2020-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9JZ052dVJwcUtldUlaakRTR0dPNTkxYTk1RWZ4M2pJbFpucVdxSVptWG03T3FYbG1RVGVKd3FRVDhJSjRwUndqTC1Mc3BYZHRBVnpHSDJ3V0t4QnVCTC1xZFVLeE5lNlczTFBlV19wQmJBdw?oc=5","date":"2025-07-26","type":"pipeline","source":"Insightace Analytic","summary":"Heparinoid Market Exclusive Research Report 2025 - Insightace Analytic","headline":"Heparinoid Market Exclusive Research Report 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQQlQ2ci0zX1hXUUVtQl9LWllzYzV4LWFhZWJnOFJfcktNOWNJelVmRkZhSlF3R1Jlc1JudjZLZnBPanlKeXdzbVF2aGxLOFdEU2h3UnBTZFVJWDFrY1pwSk92QXREVXJiN2d5NnhHbFlZWkVXY25VdnpjOC00VDh6eEIwUjg?oc=5","date":"2025-03-14","type":"regulatory","source":"The Pharma Letter","summary":"FDA slaps CRL on Seikagaku’s BLA for condoliase - The Pharma Letter","headline":"FDA slaps CRL on Seikagaku’s BLA for condoliase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxPVTNPUzRDZGNud2lsT0Q2UUJ1dllpajVtRjlPcmNweTFDdkQ0d19mejdLdlZSa3RzcmlwOGt1Y2N4SzVlSTlLTDNMYWpBTnFYU3pGd2prQ0FUTlU1bVByUDNlMEVmUUc1dVlKSmxkd19BOTFMMnZDNnZBNEN2SnozeVFBc0pNaE1wVkJGMWdYZ0ozMDdzejdnV1BNMFZwZENhQ2lPWVNtT1Z5TjZKNzdsMy03aG1UUHdFOV9RWEVrMThqVWt0UW1VelVwRGVIdGQ1bjBkVUFMTUcxREE0MUZrU25ycy1zWTQ2S2QwVVg5LW83UHdiZ0QzNlNWUFlxUWhwemlYci1HS08zTUp1TlJZR1lBU3hSbzdRV3IxQTJBQQ?oc=5","date":"2024-09-26","type":"trial","source":"BioSpace","summary":"Ferring Presents Efficacy and Safety Data From Two Phase 3 Studies for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at NASS 2024 - BioSpace","headline":"Ferring Presents Efficacy and Safety Data From Two Phase 3 Studies for Investigational Treatment, SI-6603 (condoliase), ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE4ySnZUNWo5d2RVOWo2ZllmZFBpWkVaWnRydlVhQ0JaLTRTS2xwWVF4MTRzb2g0R3BVU1lpVms0NEh3YlR2VWJfRWZ5YTVZN3Fsb2tydTE0YUdDTXc2SGdMRnQyb1AyZC1yUUJPSEVKdDNqQQ?oc=5","date":"2024-04-23","type":"pipeline","source":"Straits Research","summary":"Tennis Elbow Treatment Market to Grow at a CAGR of 5.8% by 2032 - Straits Research","headline":"Tennis Elbow Treatment Market to Grow at a CAGR of 5.8% by 2032","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxQTUxRUUpCZnlLUl8zODQ2eEd2S1ktMUx5dEZfV3QxTzAyNFVjbnRIT0dwM3dlOVE2bGxfbGwzNGNNaUg3LTNzOElOTy0zWVd2NENXVzdUOERZY3U3TG11azlYQUpxbk5USDlQaC05TkpTeTN0dC1uWTBzNWU4dGxFdm1fQlVsVWVaRWlKeXRrRnJuQWtleDlxMmNxakNnLVkzQjZQdUdHQk53cjI3OWxrNVhSMm9YeUtTOXNCSHhZVVM2OTVCVEhyQ1dvYmdxR2d1WU82SW54a2RaTlphNXluazl4Vm5WTm15dDd1MUxjWUJEV2VVcjIxeTk0eFh1TzFUYWQ1WFlKcWxSTTQtRVIta2ZtN1pBcjc1R1phNDZNTVFvR3BU?oc=5","date":"2023-05-01","type":"regulatory","source":"Business Wire","summary":"Global Custom Synthesis & Manufacturing (CSM) Market Report 2023: Escalating Demand for Specialty Chemicals Drives Growth - ResearchAndMarkets.com - Business Wire","headline":"Global Custom Synthesis & Manufacturing (CSM) Market Report 2023: Escalating Demand for Specialty Chemicals Drives Growt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPalY4bWtKaFhocmhCR2g3LVJwUnJ5dlhlNGRYVFRQcVNScWNoa2NOb3RHUWNrdHlzQUVMQnhXYkY4VV9ISHdPTUZYS3hpam5iLUI3bk5zMmYtRjQwOVl4OFJzdTR3ZmRFOGZ5ZmNUc0dyN1ZGd3UtME9YLWZ0MDFjOVcwajRjQkVLUG1YdkljMThNSmE0QndPaDVSY1JKNE4wS0VqNWZFc3QzNDBWZDExNmNTemtnR1ZzV3JHV0ZsX2V5UHp0Z3FNMjdkT0swQQ?oc=5","date":"2023-02-16","type":"pipeline","source":"PR Newswire","summary":"Dalton Announces Major Expansion in Commercial Sterile Manufacturing Capacity - PR Newswire","headline":"Dalton Announces Major Expansion in Commercial Sterile Manufacturing Capacity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOMXVmc21waUtZM1F0Y0RCTVlsdnExV0lMQnhuLW1tT3Y2NEVPcGo4TnpOREdnRXh0LW5tQVRUZ01TVVRfc3RLYUI4cm44UEhiT2NuLUFXSWxCZWZraVZ0M3hrUEFXb0JIaWI2LWFHSmZPaDVMMGpZcWdJVnJTWXkwVTFCVGczMHl5STItd1d6Tmc?oc=5","date":"2020-04-15","type":"deal","source":"Contract Pharma","summary":"Seikagaku Acquires Dalton Pharma Services - Contract Pharma","headline":"Seikagaku Acquires Dalton Pharma Services","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTFBxNy1DWk9iZDdGN0I3UTEwazB0bmFwZnhGODJ5T29JdlpxQUJKRUtQS2RJOU93aHpPcTRWQnBiamsxQmVIdFV5TVR5Ulo2dmp6WElMNUpseEk?oc=5","date":"2017-08-09","type":"pipeline","source":"TradingView","summary":"4548 Stock Price and Chart — TSE:4548 - TradingView","headline":"4548 Stock Price and Chart — TSE:4548","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNMVlNRUN2ajJTYl96Qms2ejJJZUZjYmx2bUN4UkQ5bUlvWC1ZaU5MVk9UdDlnQjNicFJ6RG43WEI5c040SXUtSF9jOV9DRTdfUVNlU2hWQkJ1ZEFnaVl6bW9zZzUwVlFCS2sweVhzOE1oakJEV0dRREotdll6cTNkTmNFMDVpQQ?oc=5","date":"2016-09-23","type":"deal","source":"Orthopedics This Week","summary":"Will a $95 Million Deal Bring Chemonucleolysis Back? - Orthopedics This Week","headline":"Will a $95 Million Deal Bring Chemonucleolysis Back?","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":2,"phase_1":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}